YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Inspire Leadership NetworkMee the 2026 Philadelphia ORBIE Award Winners Leading CIOs and CISOs honored for leadership, innovation, and business impact at the Philadelphia ORBIE Awards on September 25, 2026 at Philadelphia Marriott Downtown…
WARREN, N.J., Sept. 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept. 22, 2026, the company approved non-statutory stock options to purchase an aggregate of 51,270 shares of its common stock and 3…
– Completion of BLA submission expected in Q4 2026 – WARREN, N.J., Sept. 21, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. t…
PTC Therapeutics (PTCT) heads into its next earnings report with consensus EPS forecasts unchanged over the past month, even as the stock ticked 0.6% higher in the last session to close at $68. Recent trading has been choppy for PTC Therap…
ImmunityBio IBRX shares soared 7% in the last trading session to close at $8.46. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.7% loss over the past four we…
Ernexa Therapeutics Inc. Dr. Spiegel brings decades of global clinical development, regulatory and oncology leadership experience, including former Chief Medical Officer roles at Schering-Plough and PTC Therapeutics Appointment further str…
WARREN, N.J., Aug. 27, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:PTC Therapeutics, Inc. Logo Wells Fargo 21st Annual Healthcare Conference Thursda…
Keros Therapeutics KROS is set to receive a $20 million development milestone from Takeda after the first patient was dosed in the phase III ELRiSE study of elritercept. The payment adds near-term financial flexibility while advancing a pa…
Keros Therapeutics KROS reported a second-quarter 2026 loss of $1.45 per share, wider than the Zacks Consensus Estimate of a loss of $1.25. Revenues fell to zero from $18.2 million a year earlier. The investment case now rests heavily on r…
– 17 abstracts and presentations planned at SSIEM Symposium – – Real-world evidence demonstrates significant diet liberalization achieved with Sephience while maintaining target blood Phe levels – – Continued evidence of meaningful benefit…
This article first appeared on GuruFocus. Wells Fargo is looking beyond mega-cap technology for the market's next winners, highlighting PTC Therapeutics (NASDAQ:PTCT) and Dick's Sporting Goods (NYSE:DKS) as two stocks it believes can outpe…
(RTTNews) - PTC Therapeutics, Inc., (PTCT) has agreed to acquire ST-920, a BLA-stage one-time AAV gene therapy for Fabry disease from Sangamo Therapeutics in a $111 million upfront deal plus milestone payments. Fabry disease is a rare inhe…
Sangamo Therapeutics, Inc. PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program Proposed sales subject…
– Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization – – ST-920 is a one-time administered AAV gene therapy for the enzyme deficient in Fabry disea…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Recent analysis of PTC Therapeutics points to price targets clustering in a broad band that runs…
PTC Therapeutics (PTCT) has been beaten down lately with too much selling pressure. While the stock has lost 20.3% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analyst…
PTC Therapeutics (PTCT) reported $360.52 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 101.5%. EPS of $0.92 for the same period compares to -$0.83 a year ago. The reported revenue represents…
This article first appeared on GuruFocus. Total Revenue: Record quarterly revenue of $361 million. Product Revenue: $239 million, representing over 100% growth compared to $118 million in Q2 2025. Sephience Revenue: $151 million in global…
PTC Therapeutics (PTCT) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of a loss of $0.17 per share. This compares to a loss of $0.83 per share a year ago. These figures are adjusted for non-recur…
– Robust Q2 performance with total revenue of $361 million, including $239 million of product revenue – – Full-year 2026 expected total revenue increased to $1.18 to $1.28 billion, with full-year product revenue guidance raised to $850 to…
Wall Street expects a year-over-year decline in earnings on higher revenues when BioMarin Pharmaceutical (BMRN) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company'…
Wall Street expects a year-over-year increase in earnings on higher revenues when PTC Therapeutics (PTCT) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earn…
CONSHOHOCKEN, Pa., July 23, 2026 /PRNewswire/ -- Leading private markets investment management firm Hamilton Lane (Nasdaq: HLNE) announced that its Board of Directors elected Michael Schmertzler as a new independent director, effective Jul…
uniQure N.V. QURE now represents more than a single-program gene therapy story. Its profile is being reshaped by faster regulatory pathways, a narrower operating model and clinical work in rare neurological diseases. Those trends matter be…
uniQure N.V. QURE has surged as investors reassessed AMT-130, its lead gene therapy candidate for Huntington's disease. The question is whether the move already reflects too much optimism. Valuation, earnings quality, estimate trends and r…
uniQure N.V. QURE remains a catalyst-driven gene therapy stock, with AMT-130 shaping most of the investment debate. The program targets Huntington's disease, an area where disease-modifying options remain absent. Recent FDA feedback, a tar…
WARREN, N.J., July 16, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its second quarter 2026 financial results and provide an update on the company…
Neil Gregory Almstead, the chief technical ops officer of PTC Therapeutics, Inc. (NASDAQ:PTCT), sold 2,464 shares of common stock on July 9, 2026, at $90.25 per share, according to an SEC Form 4 filing. Transaction summary Metric Value Tra…
Key Points The transaction generated $222,376 in gross proceeds, realized through the exercise of 2,464 options at $46.54 and their immediate sale at a weighted average price of $90.25. The disposition represented 4% of the insider’s direc…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. PTC Therapeutics stock has delivered a 116.6% return over the past three years, yet current valuation checks suggest th…
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. PTC Therapeutics (PTCT) was recently added to three Russell 2000 Defensive indexes, including value and growth focused variants. Th…
PTC Therapeutics PTCT has built a diversified global commercial portfolio across multiple rare disease indications, providing a strong foundation for sustainable revenue growth. Sephience: PTCT's Major Growth Driver PTC's growth largely de…
[Heart Health Concept] Eoneren/E+ via Getty Images As Q2 2026 earnings season approaches, healthcare stocks are drawing investor attention as markets assess demand across care delivery, diagnostics, life sciences, pharmaceuticals, medical…
Shares of Immunome IMNM have witnessed a sharp increase over the past month, primarily driven by the growing investor confidence in the company's lead asset, varegacestat, and broader clinical progress. IMNM's Price Performance Shares of I…
For Immediate Release Chicago, IL – July 10, 2026 – Today, Zacks Investment Ideas feature highlights Health Care Sector ETF XLV, Biotech ETF XBI, Eli Lilly (LLY), Exelixis EXEL, PTC Therapeutics PTCT, Fortrea Holdings FTRE and Illumina ILM…
Agilent Technologies A shares have lost 5.2% in the year-to-date period, underperforming the Zacks Medical industry's 2.8% growth. The dip reflects cautious laboratory spending and a challenging macroeconomic environment. However, Agilent…